Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: An update

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 253-260

  Destro, Maurizio ^a   Cagnoni, Francesca ^a   D'Ospina, Antonio ^a   Ricci, Alessandra Rossi ^a   Demichele, Elena ^a   Peros, Emmanouil ^a   Zaninelli, Augusto ^b   Preti, Paola ^c  

^a Stradella Hospital of Broni Stradella   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Amlodipine; Blood pressure; HCTZ; Hydrochlorothiazide; Hypertension; Valsartan

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS VALSARTAN; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN 2 RECEPTOR; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; VALSARTAN; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; COMBINATION CHEMOTHERAPY; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; HEART MUSCLE CONTRACTILITY; HUMAN; HYPERTENSION; KIDNEY VASCULAR RESISTANCE; NONHUMAN; PATIENT ATTITUDE; PATIENT COMPLIANCE; REVIEW; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; VASODILATATION; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; DRUG EFFECT; METHODOLOGY;

AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; TETRAZOLES; VALINE;

EID: 78649665398     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s6805     Document Type: Review

References (39)

1. Kearney P, Whelton M, Reynolds K, Muntner P, Whelton P, He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365(9455):217-223.
2. Chobanian A, Bakris G, Black H. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
3. Wolf-Maier K, Cooper R, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10-17.
4. Antikainen R, Moltchanov V, Chukwuma C, et al. Trends in the prevalence, awareness, treatment and control of hypertension: The WHO MONICA Project. Eur J Cardiovasc Prev Rehabil. 2006;13:13-29.
5. Mancia G, De Backer G, Dominiczak A, et al; for ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension. J Hypertens. 2007;25(9):1751-1762.
6. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertension. 2009;27:923-934.
7. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.
8. Mancia G, Brown M, Castaigne A, et al. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension. 2003;41(3):431-436.
9. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: Subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens. 2007;9(5):355-364.
10. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil- Trandolapril Study (INVEST): A randomized controlled trial. JAMA. 2003;290(21):2805-2816.
11. Grosso A, Jin J, Chen J. An 8-week, multi-centre, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertension. Novartis Full Clinical Study Report. 2008.
12. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomized controlled trial. Lancet. 2005;366(9489):895-906.
13. Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): A randomised, open-label, blinded endpoint morbiditymortality study. Lancet. 2007;369:1431-1439.
14. Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007;29(2):279-289.
15. Elliott WJ. What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens. 2008;10(1 Suppl 1):20-26.
16. Phillips L, Branch W, Cook C, et al. Clinical inertia. Ann Intern Med. 2001;135:825-834.
17. Bailey K, Grossardt B, Graves J. Novel use of Kaplan-Meier methods to explain age and gender differences in hypertension control rates. Hypertension. 2008;51:841-847.
18. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428.
19. Devereux RB, de Faire U, Fyhrquist F, et al. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. Curr Med Res Opin. 2007;23(2):259-270.
20. Bangalore S, Messerli FH, Cohen JD, et al. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: An INternational VErapamil SR-Trandolapril (INVEST) substudy. Am Heart J. 2008;156(2):241-247.
21. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4(6):393-404.
22. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively designed overviews of randomised trials. Lancet. 2003;362(9395): 1527-1535.
23. Gradman A, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep. 2002;4:343-349.
24. Ma Y, Schwartzman M, Roman R. Altered renal P-450 metabolism of arachidonic acid in Dahl salt-sensitive rats. Am J Physiol. 1994;267: R579-589.
25. Laffer C, Gainer J, Waterman M, et al. The T8590C polymorphism of CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension. Hypertension. 2008;51:767-772.
26. Laffer C, Laniado-Schwartzman M, Wang M, Nasjletti A, Elijovich F. Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic acid in human salt-sensitive versus salt-resistant hypertension. Circulation. 2003;107:574-578.
27. Novartis. CVEA489A2104: A multi-center, multiple dose, open-label, four-cohort, parallel study to assess the pharmacokinetic drug interaction following co-administration of valsartan, hydrochlorothiazide and amlodipine in patients with hypertension. Novartis Clinical Trials Results Database. 2009. Available from: http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp.
28. Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: The EX-EFFeCTS Study. J Am Soc Hypertens. 2008;2:294-302.
29. Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: A randomized clinical trial. Hypertension. 2009;54:32-39.
30. Deeks E. Amlodipine/valsartan/hydrochlorothiazide: Fixed-dose combination in hypertension. Am J Cardiovasc Drugs. 2009;9:411-418.
31. Novartis. CVEA489A2302: An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine inpatients with moderate to severe hypertendion. Novartis Clinical Trials Results Database. 2009. Available from: http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp.
32. Novartis. FDA approves Exforge HCT® - the only high blood pressure treatment to combine three medications in a single pill. 2009. Available from: http://www.novartis.com/newsroom/media-releases/en/2009/1310474.shtml. Accessed June 3, 2009.
33. Schrader J, Salvetti A, Calvo C, et al. The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. Int J Clin Pract. Feb 2009;63(2):217-225.
34. Kjeldsen SEAT, Sierra ADL, et al. Amlodipine and valsartan: calcium channel blockers/angiotensin II receptor blockers combination for hypertension. Drug Eval. 2007;4:31-40.
35. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm. 2007;64(12):1279-1283.
36. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12(3):239-245.
37. Destro M, Crikelair N, Yen J, Glazer R. Triple therapy with amlodipine, valsartan, and HCTZ in Stage 2 hypertensive patients. Curr Med Res Opin. In press.
38. Yusuf SW, Ali SS, Swafford J, et al. Culture-positive and culture-negative endocarditis in patients with cancer: A retrospective observational study, 1994-2004. Medicine. 2006;85(2):86-94.
39. Novartis Pharmaceuticals Corporation (East Hanover NJ). Exforge HCT®: Highlights of prescribing information. 2009. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022314lbl.pdf. Accessed April 30, 2009.